Skip to main content
. Author manuscript; available in PMC: 2017 Oct 15.
Published in final edited form as: J Immunol. 2016 Sep 7;197(8):3120–3129. doi: 10.4049/jimmunol.1600690

FIGURE 1.

FIGURE 1

Knockdown of RIPK1 markedly exacerbates α-galactosylceramide (αGalCer)-induced liver injury and causes mortality. Groups of mice were pretreated with scrambled (Cont ASO) or RIPK1 ASO every other day for 5 times to silence RIPK1 prior to αGalCer (4μg/mouse i.p.). (A) Serum ALT values at indicated times after αGalCer. *p<0.05 vs. scrambled controls at 8hr; representative of three separate experiments. (B) Mouse survival by 24 hr after αGalCer. *p<0.05 vs. scrambled controls. (C) H&E staining of liver sections at indicated times after αGalCer (x40). (D) Western blotting of whole liver lysates for RIPK1 at indicated times after αGalCer.